| Assay ID | Title | Year | Journal | Article |
|---|
| AID736357 | Apparent permeability in dog RRCK cells | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID429287 | Inhibition of CYP3A4 | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID736364 | Apparent intrinsic clearance in human liver microsomes | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID392535 | Antiviral activity against Sendai virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID293321 | Metabolic stability human liver microsomes | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID1500737 | Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by spectrophotometric analysis | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. |
| AID429281 | Antiviral activity against RSV assessed as inhibition of viral replication by cell based assay | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID293319 | Cytotoxicity against HEp2 cells | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID392513 | Antiviral activity against HIV1 | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID293322 | Permeability across human Caco-2 cells | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID429294 | Antiviral activity against RSV infected in BALB/c mouse assessed as log reduction in viral titer | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID1350239 | Oral bioavailability in Balb/c mouse at 10 mg/kg administered as single dose via gavage by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID308545 | Antiviral activity against RSV long A with F1 protein K394R mutation in HEp2 cells | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. |
| AID1206974 | Solubility of the compound in phosphate buffer at pH 6.5 after overnight incubation by LYSA method | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID429284 | Inhibition of CYP2C9 | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID293328 | Antiviral activity against RSV infected BALB/c mouse per lung at 50 mg/kg/day | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID736351 | Apparent intrinsic clearance in rat liver microsomes assessed per mg protein | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID429289 | Oral bioavailability in rat at 5 mg/kg | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID1660198 | Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microscopic analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
| Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1 |
| AID1206975 | Permeability of the compound at 150 uM by PAMPA | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID1350232 | Clearance in Balb/c mouse at 1 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID392534 | Antiviral activity against Poliovirus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID583681 | Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as reduction in epithelial lining fluid viral load | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
| Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. |
| AID293320 | Therapeutic index, ratio of CC50 for HEp2 cells to EC50 for RSV Long | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID1350236 | Cmax in Balb/c mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID1206976 | Clearance in human liver microsomes at 1 uM | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID429283 | Permeability across human Caco-2 cells | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID368973 | Antiviral activity against RSV infected human Hep2 cells assessed as reduction of plaque formation pretreated 2 hrs before viral infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| RSV604, a novel inhibitor of respiratory syncytial virus replication. |
| AID429295 | Antiviral activity against RSV infected in BALB/c mouse assessed as reduction viral replication by RT-PCR | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID429282 | Metabolic stability in human liver mocrosomes | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID293325 | AUC in dog at 0.5 mg/kg, po | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID293331 | Inhibition of cytochrome P450 | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID392523 | Antiviral activity against Human rhinovirus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID1206972 | Antiviral activity against Respiratory syncytial virus A infected in human Hep2 cells assessed as reduction of virus-induced cytopathic effect after 6 days by CCK-8 assay | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID293330 | Antiviral activity against RSV infected cotton rat per lung at 50 mg/kg/day | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID1500738 | Cytotoxicity against human Hep2 cells after 4 days | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. |
| AID368974 | Antiviral activity against RSV infected human Hep2 cells assessed as reduction of plaque formation treated 6 hrs after viral infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| RSV604, a novel inhibitor of respiratory syncytial virus replication. |
| AID1206977 | Clearance in mouse liver microsomes at 1 uM | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID293332 | Partition coefficient, log P at pH 6.5 | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID1350241 | Antiviral activity against human respiratory syncytial virus A2 infected in Balb/c mouse assessed as reduction in lung viral load at 50 mg/kg, po administered once daily pretreated for 1 hr on day 0 followed by viral infection and subsequent compound dosi | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID1350233 | Half life in Balb/c mouse at 1 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID1350238 | AUC (0 to infinity) in Balb/c mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID1190756 | Resistance index, ratio of EC50 for VP-14637 resistant respiratory syncytial virus Long expressing F protein D489Y mutant to EC50 for wild type Respiratory syncytial virus B1 | 2015 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
| 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate. |
| AID369150 | Antiviral activity against RSV infected human Hep2 cells assessed as plaque reduction treated concurrently with viral infection by plaque reduction assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| RSV604, a novel inhibitor of respiratory syncytial virus replication. |
| AID583680 | Antiviral activity against respiratory syncytial virus long strain infected in po dosed cotton rat assessed as log reduction in viral load at 5000 ng/h/ml compound AUC | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
| Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. |
| AID736359 | Volume of distribution in steady state in rat | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID1206973 | Cytotoxicity against human Hep2 cells assessed as cell viability after 6 days by CCK-8 assay | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID1350234 | Volume of distribution in Balb/c mouse at 1 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID1206979 | Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysis | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID429286 | Inhibition of CYP2D6 | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID429285 | Inhibition of CYP2C19 | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID1261339 | Antiviral activity against RSV | 2015 | Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
| Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. |
| AID293318 | Antiviral activity against RSV Long in HEp2 cells assessed as reduction of virus-induced cytopathic effect | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID736358 | Half life in iv dosed rat | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID736362 | Apparent intrinsic clearance in human hepatocytes assessed per million cells | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID1190755 | Resistance index, ratio of EC50 for drug resistant respiratory syncytial virus Long expressing F protein Q494L mutant to EC50 for wild type Respiratory syncytial virus B1 | 2015 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
| 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate. |
| AID1190679 | Selectivity ratio of EC50 for Respiratory syncytial virus A Long harboring F protein T335I mutant infected in human Hep2 cells to EC50 for wild-type Respiratory syncytial virus A Long infected in human Hep2 cells | 2015 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
| The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1. |
| AID1206980 | Inhibition of CYP2D6 in human liver microsomes by LC-MS/MS analysis | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID293323 | AUC in mouse at 10 mg/kg, po | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID1206978 | Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
| Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. |
| AID1350231 | Cytotoxicity against human Hep2 cells after 5 days by CCK8 assay | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID1350237 | Tmax in Balb/c mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID429292 | Volume of distribution at steady state in rat at 1 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID1660200 | Selectivity index, ratio of CC50 for human HeLa cells to EC50 GFP-fused RSV 224 fusion protein infected in human HeLa cells | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
| Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1 |
| AID293326 | AUC in cynamologous monkey at 0.5 mg/kg, po | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID736360 | Oral bioavailability in rat | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID429288 | Inhibition of CYP1A2 | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID429290 | Cmax in rat at 5 mg/kg, po | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID736350 | Apparent intrinsic clearance in human liver microsomes assessed per mg protein | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID429293 | Terminal half life in rat at 1 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID1350230 | Inhibition of RSV long strain fusion protein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by CCK8 assay | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID736356 | Octanol-neutral buffer partition co-efficient, log D of the compound at pH 7.4 | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID429291 | Total clearance in rat at 1 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
| Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. |
| AID736361 | Intrinsic clearance in rat plasma | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID1660199 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 3 days by ATPlite assay | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
| Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1 |
| AID1190754 | Resistance index, ratio of EC50 for drug resistant respiratory syncytial virus B1 expressing F protein L141F mutant to EC50 for wild type Respiratory syncytial virus B1 | 2015 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
| 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate. |
| AID392531 | Antiviral activity against influenza virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID293324 | AUC in rat at 5 mg/kg, po | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID736353 | Apparent intrinsic clearance in mouse liver microsomes assessed per mg protein | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID1350235 | AUC (0 to infinity) in Balb/c mouse at 1 mg/kg, iv administered as single bolus dose by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Feb-08, Volume: 9, Issue:2
| Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection. |
| AID736365 | Antiviral activity against Respiratory syncytial virus A2 infected in A549 cells after 3 days by CelltitreGlo assay | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
| Non-benzimidazole containing inhibitors of respiratory syncytial virus. |
| AID293321 | Metabolic stability human liver microsomes | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID293322 | Permeability across human Caco-2 cells | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID293319 | Cytotoxicity against HEp2 cells | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID293320 | Therapeutic index, ratio of CC50 for HEp2 cells to EC50 for RSV Long | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| AID293318 | Antiviral activity against RSV Long in HEp2 cells assessed as reduction of virus-induced cytopathic effect | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
| Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |